Kancera is headquartered at the Karolinska Institute Science Park in Stockholm, Sweden, a world-leading hub for medical research and innovations. The company’s focus is to develop a new class of small molecule drugs that control disease promoting immune and cancer cells with precision, by targeting the fractalkine axis. Kancera’s fractalkine blocking drug candidates have the potential to treat resistant cancers and severe inflammatory conditions.
Kancera is listed on Nasdaq OMX First North Premier.
"Kancera has, since its foundation, conducted world class drug discovery and advanced candidate drugs into clinical development. Now we are ready to take the next transformational step and establish a pipeline with multiple late-stage projects with significant value potential."
Kancera’s strategy is to develop innovative candidate drugs with solid IP, demonstrate efficacy in human and based on these results, develop drug candidates into approved pharmaceutical products in partnership with other pharmaceutical companies.
A core component of the business model is to develop and commercialize products by partnering with other pharmaceutical companies where Kancera out-licenses the development and commercialization rights. This can be out-licensing of either global rights, or rights in certain geographies and specific therapeutic areas. The scope of the business model allows for Kancera to keep development and commercialization rights in certain markets.
The business model includes the possibility for Kancera to earn revenues either in the form of upfront payments, milestone payments and sales royalties from partners or from product sales in geographies where Kancera has retained commercialization rights.
Kancera’s management team has extensive expertise and experience of translating medical discovery into candidate drugs and developing these into marketed products in partnership with other pharmaceutical companies. From its foundation in 2010, Kancera has discovered, patented and published several new preclinical candidate drugs, advanced candidate drugs into clinical development and demonstrated safety and proof-of-mechanism in human.
Kancera's board of directors consists of individuals with extensive experience from senior positions in their respective areas of expertise.
Chairman of the board, lawyer Erik Nerpin, has over 25 years of experience in the field of business law. Professor Petter Brodin, MD PhD, Charlotte Edenius, MD PhD, Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all distinguished scientific advisers and board members of Kancera.